Parity, pregnancy and neonatal outcomes in women treated for hyperprolactinaemia compared with a control group
- 20 July 2007
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 67 (3) , 393-397
Abstract
Summary: Objective Infertility is a common problem in women with hyperprolactinaemia. There are limited data on the fertility and pregnancy course among these women. The objective was to study parity, pregnancy and neonatal outcomes in women with hyperprolactinaemia as compared with a control group.Design Register study.Patients Two hundred and seventy‐one female patients treated for primary hyperprolactinaemia were identified in the hospital record archives between 1974 and 2002. For each patient four comparison subjects, matched by sex, birth year and county of residence were identified in the Register of Population. Data were retrieved from the Swedish medical birth register and were analysed using logistic regression and analysis of variance.Measurements Parity, maternal age at first delivery, weeks of gestation, induction of labour, caesarean delivery, multiple birth, Apgar score, birth weight, length, sex, congenital malformations, neonatal care.Results One hundred and sixty‐two deliveries in the hyperprolactinaemia group and 1220 deliveries in the control group were analysed. Patients with hyperprolactinaemia were significantly older at their first pregnancy than their controls: 29·0 (± 4·4) and 27·2 (± 4·8) years, respectively (P = 0·0002). Furthermore, parity was inversely associated with hyperprolactinaemia status (P for trend = 0·0009). The odds of having three or more children were threefold lower among the patients (OR 0·31 (95% CI 0·16, 0·60)). There were no differences between patients and controls with respect to pregnancy complications, delivery or neonatal outcome variables.Conclusions We found no evidence of increased risk of pregnancy complications or adverse pregnancy outcomes in women with treated hyperprolactinaemia. However, the patients were older at their first pregnancy and had a reduced overall parity.Keywords
This publication has 34 references indexed in Scilit:
- Hyperprolactinaemia in 271 women: up to three decades of clinical follow‐upClinical Endocrinology, 2005
- Pituitary tumors and pregnancyGrowth Hormone & IGF Research, 2003
- Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 PatientsThe Journal of Clinical Endocrinology & Metabolism, 1999
- Long‐term follow‐up of patients with hyperprolactinaemiaClinical Endocrinology, 1996
- Outcome and long-term effects of pregnancy in women with hyperprolactinaemiaEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 1992
- Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic womenEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 1992
- Dopamine agonists and pituitary tumor shrinkageEndocrine Reviews, 1992
- Is pregnancy the best treatment for hyperprolactinaemia?Human Reproduction, 1989
- The safety of bromocriptine in hyperprolactinaemic female infertility: a literature reviewCurrent Medical Research and Opinion, 1986
- Bromocriptine as Primary Therapy for Prolactin-Secreting Macroadenomas: Results of a Prospective Multicenter Study*The Journal of Clinical Endocrinology & Metabolism, 1985